LOS ANGELES, CA -- (Marketwired) -- 10/11/13 -- SK3 Group, Inc. (OTC Pink: SKTO) ("the Company") announced that it plans to release 3rd quarter results by month's end.
As part of the Company's effort to enhance its operations, management is improving its reporting efforts and as a result will issue the 3rd quarter results early. "We are continuing to bolster our managerial services and as a result we will be better able to report to our shareholders results of operations for the 3rd quarter and 9 months ending September 30, 2013, earlier than required," stated Mr. Artemus Mayor, President of SK3 Group, Inc. "We will also post to our web-site a pre-recorded conference call with the officers of the Company shortly after the reporting of our 3rd quarter fiscal results," Mr. Mayor added. "While we had said before we may do a management conference call earlier in the month, we think it prudent to wait until after we have released the financials so that management can better respond to that information and any investor questions relating thereto."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, enhancing the team and its capabilities, and cleaning up various corporate issues such as the CUSIP, dividend, name change, audits, and other operational issues.
"The Company had a terrific third quarter and when the financial results are released investors will see that we have continued in our long term focus to collect receivables and enhance revenues, increase cash on hand while investing intelligently in the business, focus on personnel and acquiring the right business relationships, and otherwise expand the Company's role in the medical marijuana space," said Kevin Allyn, the Company's Chairman. "We are looking forward to sharing more details with our investors on each of these points in the near future. But investors will be able to measure our long term progress by how we fare against our milestones."
Previously the Company announced, that its wholly owned subsidiary Medical Greens announced that it has obtained the exclusive license for Dharmanol for the State of California. Dr. Charles Apel, of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc.
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and no responsibility or obligation may be assumed or exists to update the information included herein for events occurring after the date
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.